{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,22]],"date-time":"2026-10-22T21:36:32Z","timestamp":1792704992218,"version":"4.5.0"},"reference-count":80,"publisher":"Springer Science and Business Media LLC","issue":"10","license":[{"start":{"date-parts":[[2013,8,27]],"date-time":"2013-08-27T00:00:00Z","timestamp":1377561600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-sa\/3.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Nat Rev Clin Oncol"],"published-print":{"date-parts":[[2013,10]]},"DOI":"10.1038\/nrclinonc.2013.153","type":"journal-article","created":{"date-parts":[[2013,8,27]],"date-time":"2013-08-27T13:06:07Z","timestamp":1377608767000},"page":"588-598","source":"Crossref","is-referenced-by-count":166,"title":["The Society for Immunotherapy of Cancer consensus statement on tumour immunotherapy for the treatment of cutaneous melanoma"],"prefix":"10.1038","volume":"10","author":[{"given":"Howard L.","family":"Kaufman","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"John M.","family":"Kirkwood","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"F. Stephen","family":"Hodi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sanjiv","family":"Agarwala","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Thomas","family":"Amatruda","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Steven D.","family":"Bines","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Joseph I.","family":"Clark","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Brendan","family":"Curti","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marc S.","family":"Ernstoff","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Thomas","family":"Gajewski","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rene","family":"Gonzalez","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Laura Jane","family":"Hyde","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"David","family":"Lawson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michael","family":"Lotze","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jose","family":"Lutzky","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kim","family":"Margolin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"David F.","family":"McDermott","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Donald","family":"Morton","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anna","family":"Pavlick","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jon M.","family":"Richards","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"William","family":"Sharfman","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Vernon K.","family":"Sondak","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jeffrey","family":"Sosman","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Susan","family":"Steel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ahmad","family":"Tarhini","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"John A.","family":"Thompson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jill","family":"Titze","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Walter","family":"Urba","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Richard","family":"White","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michael B.","family":"Atkins","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2013,8,27]]},"reference":[{"key":"BFnrclinonc2013153_CR1","unstructured":"National Cancer Institute. Cancer Trends Progress Report--2011\/2012 Update [online] , (2012)."},{"key":"BFnrclinonc2013153_CR2","doi-asserted-by":"publisher","first-page":"5","DOI":"10.1634\/theoncologist.2010-0190","volume":"16","author":"C Garbe","year":"2011","unstructured":"Garbe, C., Eigentler, T. K., Keilholz, U., Hauschild, A. & Kirkwood, J. M. Systematic review of medical treatment in melanoma: current status and future prospects. Oncologist 16, 5\u201324 (2011).","journal-title":"Oncologist"},{"key":"BFnrclinonc2013153_CR3","doi-asserted-by":"publisher","first-page":"6199","DOI":"10.1200\/JCO.2009.23.4799","volume":"27","author":"CM Balch","year":"2009","unstructured":"Balch, C. M. et al. Final version of 2009 AJCC melanoma staging and classification. J. Clin. Oncol. 27, 6199\u20136206 (2009).","journal-title":"J. Clin. Oncol."},{"key":"BFnrclinonc2013153_CR4","doi-asserted-by":"publisher","first-page":"117","DOI":"10.1016\/S0140-6736(08)61033-8","volume":"372","author":"AM Eggermont","year":"2008","unstructured":"Eggermont, A. M. et al. Adjuvant therapy with pegylated interferon alfa-2b versus observation alone in resected stage III melanoma: final results of EORTC 18991, a randomised phase III trial. Lancet 372, 117\u2013126 (2008).","journal-title":"Lancet"},{"key":"BFnrclinonc2013153_CR5","doi-asserted-by":"publisher","first-page":"711","DOI":"10.1056\/NEJMoa1003466","volume":"363","author":"FS Hodi","year":"2010","unstructured":"Hodi, F. S. et al. Improved survival with ipilimumab in patients with metastatic melanoma. N. Engl. J. Med. 363, 711\u2013723 (2010).","journal-title":"N. Engl. J. Med."},{"key":"BFnrclinonc2013153_CR6","doi-asserted-by":"publisher","first-page":"2507","DOI":"10.1056\/NEJMoa1103782","volume":"364","author":"PB Chapman","year":"2011","unstructured":"Chapman, P. B. et al. Improved survival with vemurafenib in melanoma with BRAF V600E mutation. N. Engl. J. Med. 364, 2507\u20132516 (2011).","journal-title":"N. Engl. J. Med."},{"issue":"Suppl. 1","key":"BFnrclinonc2013153_CR7","first-page":"S11","volume":"6","author":"MB Atkins","year":"2000","unstructured":"Atkins, M. B., Kunkel, L., Sznol, M. & Rosenberg, S. A. High-dose recombinant interleukin-2 therapy in patients with metastatic melanoma: long-term survival update. Cancer J. Sci. Am. 6 (Suppl. 1), S11\u2013S14 (2000).","journal-title":"Cancer J. Sci. Am."},{"key":"BFnrclinonc2013153_CR8","doi-asserted-by":"publisher","first-page":"2039","DOI":"10.1158\/1078-0432.CCR-11-1823","volume":"18","author":"PA Prieto","year":"2012","unstructured":"Prieto, P. A. et al. CTLA-4 blockade with ipilimumab: long-term follow-up of 177 patients with metastatic melanoma. Clin. Cancer Res. 18, 2039\u20132047 (2012).","journal-title":"Clin. Cancer Res."},{"key":"BFnrclinonc2013153_CR9","doi-asserted-by":"publisher","first-page":"2517","DOI":"10.1056\/NEJMoa1104621","volume":"364","author":"C Robert","year":"2011","unstructured":"Robert, C. et al. Ipilimumab plus dacarbazine for previously untreated metastatic melanoma. N. Engl. J. Med. 364, 2517\u20132526 (2011).","journal-title":"N. Engl. J. Med."},{"key":"BFnrclinonc2013153_CR10","doi-asserted-by":"publisher","first-page":"2691","DOI":"10.1200\/JCO.2012.41.6750","volume":"30","author":"JS Weber","year":"2012","unstructured":"Weber, J. S., Kahler, K. C. & Hauschild, A. Management of immune-related adverse events and kinetics of response with ipilimumab. J. Clin. Oncol. 30, 2691\u20132697 (2012).","journal-title":"J. Clin. Oncol."},{"key":"BFnrclinonc2013153_CR11","doi-asserted-by":"publisher","first-page":"1388","DOI":"10.1093\/jnci\/djq310","volume":"102","author":"A Hoos","year":"2010","unstructured":"Hoos, A. et al. Improved endpoints for cancer immunotherapy trials. J. Natl Cancer Inst. 102, 1388\u20131397 (2010).","journal-title":"J. Natl Cancer Inst."},{"key":"BFnrclinonc2013153_CR12","doi-asserted-by":"publisher","first-page":"7412","DOI":"10.1158\/1078-0432.CCR-09-1624","volume":"15","author":"JD Wolchok","year":"2009","unstructured":"Wolchok, J. D. et al. Guidelines for the evaluation of immune therapy activity in solid tumors: immune-related response criteria. Clin. Cancer Res. 15, 7412\u20137420 (2009).","journal-title":"Clin. Cancer Res."},{"key":"BFnrclinonc2013153_CR13","doi-asserted-by":"crossref","DOI":"10.17226\/13058","volume-title":"Clinical practice guidelines we can trust","author":"R Graham","year":"2011","unstructured":"Graham, R., Mancher, M., Miller Wolman, D., Greenfield, S. & Steinberg, E. (Eds) Clinical practice guidelines we can trust (Institute of Medicine of the National Academies, Washington D. C., 2011)."},{"key":"BFnrclinonc2013153_CR14","unstructured":"SITC. Cancer Immunotherapy Guidelines [online] , (2013)."},{"key":"BFnrclinonc2013153_CR15","doi-asserted-by":"publisher","first-page":"2006","DOI":"10.1245\/s10434-010-1050-z","volume":"17","author":"SJ Soong","year":"2010","unstructured":"Soong, S. J. et al. Predicting survival outcome of localized melanoma: an electronic prediction tool based on the AJCC melanoma database. Ann. Surg. Oncol. 17, 2006\u20132014 (2010).","journal-title":"Ann. Surg. Oncol."},{"key":"BFnrclinonc2013153_CR16","doi-asserted-by":"publisher","first-page":"2912","DOI":"10.1200\/JCO.2011.40.3519","volume":"30","author":"SL Wong","year":"2012","unstructured":"Wong, S. L. et al. Sentinel lymph node biopsy for melanoma: American Society of Clinical Oncology and Society of Surgical Oncology joint clinical practice guideline. J. Clin. Oncol. 30, 2912\u20132918 (2012).","journal-title":"J. Clin. Oncol."},{"key":"BFnrclinonc2013153_CR17","doi-asserted-by":"publisher","first-page":"1905","DOI":"10.1016\/S0140-6736(97)12445-X","volume":"351","author":"JJ Grob","year":"1998","unstructured":"Grob, J. J. et al. Randomised trial of interferon alpha-2a as adjuvant therapy in resected primary melanoma thicker than 1.5 mm without clinically detectable node metastases. French Cooperative Group on Melanoma. Lancet 351, 1905\u20131910 (1998).","journal-title":"Lancet"},{"key":"BFnrclinonc2013153_CR18","doi-asserted-by":"publisher","first-page":"144","DOI":"10.1016\/S1470-2045(10)70288-6","volume":"12","author":"J Hansson","year":"2011","unstructured":"Hansson, J. et al. Two different durations of adjuvant therapy with intermediate-dose interferon alfa-2b in patients with high-risk melanoma (Nordic IFN trial): a randomised phase 3 trial. Lancet Oncol. 12, 144\u2013152 (2011).","journal-title":"Lancet Oncol."},{"key":"BFnrclinonc2013153_CR19","doi-asserted-by":"publisher","first-page":"2883","DOI":"10.1200\/JCO.2003.07.116","volume":"21","author":"A Hauschild","year":"2003","unstructured":"Hauschild, A. et al. Prospective randomized trial of interferon alfa-2b and interleukin-2 as adjuvant treatment for resected intermediate- and high-risk primary melanoma without clinically detectable node metastasis. J. Clin. Oncol. 21, 2883\u20132888 (2003).","journal-title":"J. Clin. Oncol."},{"key":"BFnrclinonc2013153_CR20","doi-asserted-by":"publisher","first-page":"53","DOI":"10.1200\/JCO.2004.03.185","volume":"22","author":"BW Hancock","year":"2004","unstructured":"Hancock, B. W. et al. Adjuvant interferon in high-risk melanoma: the AIM HIGH Study--United Kingdom Coordinating Committee on Cancer Research randomized study of adjuvant low-dose extended-duration interferon Alfa-2a in high-risk resected malignant melanoma. J. Clin. Oncol. 22, 53\u201361 (2004).","journal-title":"J. Clin. Oncol."},{"key":"BFnrclinonc2013153_CR21","doi-asserted-by":"publisher","first-page":"3496","DOI":"10.1200\/JCO.2008.21.3892","volume":"27","author":"A Hauschild","year":"2009","unstructured":"Hauschild, A. et al. Prospective randomized multicenter adjuvant dermatologic cooperative oncology group trial of low-dose interferon alfa-2b with or without a modified high-dose interferon alfa-2b induction phase in patients with lymph node-negative melanoma. J. Clin. Oncol. 27, 3496\u20133502 (2009).","journal-title":"J. Clin. Oncol."},{"key":"BFnrclinonc2013153_CR22","doi-asserted-by":"publisher","first-page":"841","DOI":"10.1200\/JCO.2009.23.1704","volume":"28","author":"A Hauschild","year":"2010","unstructured":"Hauschild, A. et al. Efficacy of low-dose interferon {alpha}2a 18 versus 60 months of treatment in patients with primary melanoma of >= 1.5 mm tumor thickness: results of a randomized phase III DeCOG trial. J. Clin. Oncol. 28, 841\u2013846 (2010).","journal-title":"J. Clin. Oncol."},{"key":"BFnrclinonc2013153_CR23","doi-asserted-by":"publisher","first-page":"3789","DOI":"10.4049\/jimmunol.1290060","volume":"89","author":"AA Tarhini","year":"2012","unstructured":"Tarhini, A. A., Gogas, H. & Kirkwood, J. M. INF-\u03b1 in the treatment of melanoma. J. Immunol. 89, 3789\u20133793 (2012).","journal-title":"J. Immunol."},{"key":"BFnrclinonc2013153_CR24","doi-asserted-by":"publisher","first-page":"7","DOI":"10.1200\/JCO.1996.14.1.7","volume":"14","author":"JM Kirkwood","year":"1996","unstructured":"Kirkwood, J. M. et al. Interferon alfa-2b adjuvant therapy of high-risk resected cutaneous melanoma: the Eastern Cooperative Oncology Group Trial EST 1684. J. Clin. Oncol. 14, 7\u201317 (1996).","journal-title":"J. Clin. Oncol."},{"key":"BFnrclinonc2013153_CR25","doi-asserted-by":"publisher","first-page":"2444","DOI":"10.1200\/JCO.2000.18.12.2444","volume":"18","author":"JM Kirkwood","year":"2000","unstructured":"Kirkwood, J. M. et al. High- and low-dose interferon alfa-2b in high-risk melanoma: first analysis of intergroup trial E1690\/S9111\/C9190. J. Clin. Oncol. 18, 2444\u20132458 (2000).","journal-title":"J. Clin. Oncol."},{"key":"BFnrclinonc2013153_CR26","doi-asserted-by":"publisher","first-page":"1670","DOI":"10.1158\/1078-0432.CCR-1103-3","volume":"10","author":"JM Kirkwood","year":"2004","unstructured":"Kirkwood, J. M. et al. A pooled analysis of eastern cooperative oncology group and intergroup trials of adjuvant high-dose interferon for melanoma. Clin. Cancer Res. 10, 1670\u20131677 (2004).","journal-title":"Clin. Cancer Res."},{"key":"BFnrclinonc2013153_CR27","doi-asserted-by":"publisher","first-page":"2916","DOI":"10.1200\/JCO.2008.20.2069","volume":"27","author":"A Bottomley","year":"2009","unstructured":"Bottomley, A. et al. Adjuvant therapy with pegylated interferon alfa-2b versus observation in resected stage III melanoma: a phase III randomized controlled trial of health-related quality of life and symptoms by the European Organisation for Research and Treatment of Cancer Melanoma Group. J. Clin. Oncol. 27, 2916\u20132923 (2009).","journal-title":"J. Clin. Oncol."},{"key":"BFnrclinonc2013153_CR28","doi-asserted-by":"publisher","first-page":"218","DOI":"10.1016\/j.ejca.2011.09.028","volume":"48","author":"AM Eggermont","year":"2012","unstructured":"Eggermont, A. M. et al. Ulceration and stage are predictive of interferon efficacy in melanoma: results of the phase III adjuvant trials EORTC 18952 and EORTC 18991. Eur. J. Cancer 48, 218\u2013225 (2012).","journal-title":"Eur. J. Cancer"},{"key":"BFnrclinonc2013153_CR29","doi-asserted-by":"publisher","first-page":"145","DOI":"10.1097\/00002371-199903000-00006","volume":"22","author":"M Hernberg","year":"1999","unstructured":"Hernberg, M., Pyrhonen, S. & Muhonen, T. Regimens with or without interferon-alpha as treatment for metastatic melanoma and renal cell carcinoma: an overview of randomized trials. J. Immunother. 22, 145\u2013154 (1999).","journal-title":"J. Immunother."},{"key":"BFnrclinonc2013153_CR30","doi-asserted-by":"publisher","first-page":"43","DOI":"10.1159\/000075045","volume":"208","author":"D Pirard","year":"2004","unstructured":"Pirard, D., Heenen, M., Melot, C. & Vereecken, P. Interferon alpha as adjuvant postsurgical treatment of melanoma: a meta-analysis. Dermatology 208, 43\u201348 (2004).","journal-title":"Dermatology"},{"key":"BFnrclinonc2013153_CR31","doi-asserted-by":"publisher","first-page":"493","DOI":"10.1093\/jnci\/djq009","volume":"102","author":"S Mocellin","year":"2010","unstructured":"Mocellin, S., Pasquali, S., Rossi, C. R. & Nitti, D. Interferon alpha adjuvant therapy in patients with high-risk melanoma: a systematic review and meta-analysis. J. Natl Cancer Inst. 102, 493\u2013501 (2010).","journal-title":"J. Natl Cancer Inst."},{"key":"BFnrclinonc2013153_CR32","doi-asserted-by":"publisher","first-page":"982","DOI":"10.1002\/cncr.23251","volume":"112","author":"A Hauschild","year":"2008","unstructured":"Hauschild, A. et al. Practical guidelines for the management of interferon-alpha-2b side effects in patients receiving adjuvant treatment for melanoma: expert opinion. Cancer 112, 982\u2013994 (2008).","journal-title":"Cancer"},{"key":"BFnrclinonc2013153_CR33","doi-asserted-by":"publisher","first-page":"2370","DOI":"10.1200\/JCO.2001.19.9.2370","volume":"19","author":"JM Kirkwood","year":"2001","unstructured":"Kirkwood, J. M. et al. High-dose interferon alfa-2b significantly prolongs relapse-free and overall survival compared with the GM2-KLH\/QS-21 vaccine in patients with resected stage IIB-III melanoma: results of intergroup trial E1694\/S9512\/C509801. J. Clin. Oncol. 19, 2370\u20132380 (2001).","journal-title":"J. Clin. Oncol."},{"key":"BFnrclinonc2013153_CR34","doi-asserted-by":"publisher","first-page":"158","DOI":"10.1055\/s-0030-1250669","volume":"59","author":"C Schuhan","year":"2011","unstructured":"Schuhan, C., Muley, T., Dienemann, H. & Pfannschmidt, J. Survival after pulmonary metastasectomy in patients with malignant melanoma. Thorac. Cardiovasc. Surg. 59, 158\u2013162 (2011).","journal-title":"Thorac. Cardiovasc. Surg."},{"key":"BFnrclinonc2013153_CR35","doi-asserted-by":"publisher","first-page":"111","DOI":"10.1002\/jso.21903","volume":"104","author":"N Wasif","year":"2011","unstructured":"Wasif, N., Bagaria, S. P., Ray, P. & Morton, D. L. Does metastasectomy improve survival in patients with Stage IV melanoma? A cancer registry analysis of outcomes. J. Surg. Oncol. 104, 111\u2013115 (2011).","journal-title":"J. Surg. Oncol."},{"key":"BFnrclinonc2013153_CR36","doi-asserted-by":"publisher","first-page":"1774","DOI":"10.1245\/s10434-011-2197-y","volume":"19","author":"TC Chua","year":"2012","unstructured":"Chua, T. C. et al. Surgical management of melanoma lung metastasis: an analysis of survival outcomes in 292 consecutive patients. Ann. Surg. Oncol. 19, 1774\u20131781 (2012).","journal-title":"Ann. Surg. Oncol."},{"key":"BFnrclinonc2013153_CR37","doi-asserted-by":"publisher","first-page":"2547","DOI":"10.1245\/s10434-012-2398-z","volume":"19","author":"JH Howard","year":"2012","unstructured":"Howard, J. H. et al. Metastasectomy for distant metastatic melanoma: analysis of data from the first multicenter selective lymphadenectomy trial (MSLT-I). Ann. Surg. Oncol. 19, 2547\u20132555 (2012).","journal-title":"Ann. Surg. Oncol."},{"key":"BFnrclinonc2013153_CR38","first-page":"86","volume":"4","author":"DS Lee","year":"1998","unstructured":"Lee, D. S., White, D. E., Hurst, R., Rosenberg, S. A. & Yang, J. C. Patterns of relapse and response to retreatment in patients with metastatic melanoma or renal cell carcinoma who responded to interleukin-2-based immunotherapy. Cancer J. Sci. Am. 4, 86\u201393 (1998).","journal-title":"Cancer J. Sci. Am."},{"key":"BFnrclinonc2013153_CR39","doi-asserted-by":"publisher","first-page":"298","DOI":"10.1177\/030089160308900313","volume":"89","author":"GM Verdecchia","year":"2003","unstructured":"Verdecchia, G. M. et al. Adjuvant adoptive immunotherapy in patients with stage III and resected stage IV melanoma: a pilot study [Italian]. Tumori 89, 298\u2013300 (2003).","journal-title":"Tumori"},{"key":"BFnrclinonc2013153_CR40","first-page":"1","volume":"8","author":"YM Saenger","year":"2008","unstructured":"Saenger, Y. M. & Wolchok, J. D. The heterogeneity of the kinetics of response to ipilimumab in metastatic melanoma: patient cases. Cancer Immun. 8, 1 (2008).","journal-title":"Cancer Immun."},{"key":"BFnrclinonc2013153_CR41","doi-asserted-by":"publisher","first-page":"606","DOI":"10.1097\/COC.0b013e318209cda9","volume":"35","author":"GK Pennock","year":"2012","unstructured":"Pennock, G. K., Waterfield, W. & Wolchok, J. D. Patient responses to ipilimumab, a novel immunopotentiator for metastatic melanoma: How different are these from conventional treatment responses? Am. J. Clin. Oncol. 35, 606\u2013611 (2012).","journal-title":"Am. J. Clin. Oncol."},{"key":"BFnrclinonc2013153_CR42","doi-asserted-by":"publisher","first-page":"907","DOI":"10.1001\/jama.1994.03510360033032","volume":"271","author":"SA Rosenberg","year":"1994","unstructured":"Rosenberg, S. A. et al. Treatment of 283 consecutive patients with metastatic melanoma or renal cell cancer using high-dose bolus interleukin 2. JAMA 271, 907\u2013913 (1994).","journal-title":"JAMA"},{"key":"BFnrclinonc2013153_CR43","doi-asserted-by":"publisher","first-page":"2105","DOI":"10.1200\/JCO.1999.17.7.2105","volume":"17","author":"MB Atkins","year":"1999","unstructured":"Atkins, M. B. et al. High-dose recombinant interleukin 2 therapy for patients with metastatic melanoma: analysis of 270 patients treated between 1985 and 1993. J. Clin. Oncol. 17, 2105\u20132116 (1999).","journal-title":"J. Clin. Oncol."},{"key":"BFnrclinonc2013153_CR44","doi-asserted-by":"publisher","first-page":"155","DOI":"10.1016\/S1470-2045(09)70334-1","volume":"11","author":"JD Wolchok","year":"2010","unstructured":"Wolchok, J. D. et al. Ipilimumab monotherapy in patients with pretreated advanced melanoma: a randomised, double-blind, multicentre, phase 2, dose-ranging study. Lancet Oncol. 11, 155\u2013164 (2010).","journal-title":"Lancet Oncol."},{"key":"BFnrclinonc2013153_CR45","doi-asserted-by":"publisher","first-page":"773","DOI":"10.1517\/14712598.2012.675325","volume":"12","author":"VA Trinh","year":"2012","unstructured":"Trinh, V. A. & Hwu, W. J. Ipilimumab in the treatment of melanoma. Expert Opin. Biol. Ther. 12, 773\u2013782 (2012).","journal-title":"Expert Opin. Biol. Ther."},{"key":"BFnrclinonc2013153_CR46","doi-asserted-by":"publisher","first-page":"459","DOI":"10.1016\/S1470-2045(12)70090-6","volume":"13","author":"K Margolin","year":"2012","unstructured":"Margolin, K. et al. Ipilimumab in patients with melanoma and brain metastases: an open-label, phase 2 trial. Lancet Oncol. 13, 459\u2013465 (2012).","journal-title":"Lancet Oncol."},{"key":"BFnrclinonc2013153_CR47","doi-asserted-by":"publisher","first-page":"287","DOI":"10.1038\/bjc.1991.67","volume":"63","author":"G Pichert","year":"1991","unstructured":"Pichert, G., Jost, L. M., Fierz, W. & Stahel, R. A. Clinical and immune modulatory effects of alternative weekly interleukin-2 and interferon alfa-2a in patients with advanced renal cell carcinoma and melanoma. Br. J. Cancer 63, 287\u2013292 (1991).","journal-title":"Br. J. Cancer"},{"key":"BFnrclinonc2013153_CR48","first-page":"781","volume":"79","author":"T Dorval","year":"1992","unstructured":"Dorval, T., Fridman, W. H., Mathiot, C., Sastre, X. & Pouillart, P. Treatment of metastatic malignant melanoma with interleukin-2 [French]. Bull. Cancer 79, 781\u2013787 (1992).","journal-title":"Bull. Cancer"},{"key":"BFnrclinonc2013153_CR49","doi-asserted-by":"publisher","first-page":"975","DOI":"10.1007\/BF00577739","volume":"72","author":"H Monig","year":"1994","unstructured":"Monig, H., Hauschild, A., Lange, S. & Folsch, U. R. Suppressed thyroid-stimulating hormone secretion in patients treated with interleukin-2 and interferon-alpha 2b for metastatic melanoma. Clin. Investig. 72, 975\u2013978 (1994).","journal-title":"Clin. Investig."},{"key":"BFnrclinonc2013153_CR50","doi-asserted-by":"publisher","first-page":"179","DOI":"10.1093\/oxfordjournals.annonc.a058774","volume":"5","author":"LT Vlasveld","year":"1994","unstructured":"Vlasveld, L. T. et al. Phase II study of intermittent continuous infusion of low-dose recombinant interleukin-2 in advanced melanoma and renal cell cancer. Ann. Oncol. 5, 179\u2013181 (1994).","journal-title":"Ann. Oncol."},{"key":"BFnrclinonc2013153_CR51","doi-asserted-by":"publisher","first-page":"523","DOI":"10.1002\/ijc.2910620506","volume":"62","author":"F Farace","year":"1995","unstructured":"Farace, F. et al. Low-dose IL-2 treatment: activation of discrete T- and NK-cell sub-populations in vivo. Int. J. Cancer 62, 523\u2013528 (1995).","journal-title":"Int. J. Cancer"},{"key":"BFnrclinonc2013153_CR52","doi-asserted-by":"publisher","first-page":"50","DOI":"10.1159\/000246315","volume":"192","author":"M Fleischmann","year":"1996","unstructured":"Fleischmann, M., Celerier, P., Bernard, P., Litoux, P. & Dreno, B. Long-term interferon-alpha therapy induces autoantibodies against epidermis. Dermatology 192, 50\u201355 (1996).","journal-title":"Dermatology"},{"key":"BFnrclinonc2013153_CR53","first-page":"1341","volume":"2","author":"EG Trehu","year":"1996","unstructured":"Trehu, E. G. et al. Phase I trial of interleukin 2 in combination with the soluble tumor necrosis factor receptor p75 IgG chimera. Clin. Cancer Res. 2, 1341\u20131351 (1996).","journal-title":"Clin. Cancer Res."},{"key":"BFnrclinonc2013153_CR54","first-page":"1203","volume":"4","author":"DF McDermott","year":"1998","unstructured":"McDermott, D. F. et al. A two-part phase I trial of high-dose interleukin 2 in combination with soluble (Chinese hamster ovary) interleukin 1 receptor. Clin. Cancer Res. 4, 1203\u20131213 (1998).","journal-title":"Clin. Cancer Res."},{"key":"BFnrclinonc2013153_CR55","first-page":"1389","volume":"6","author":"J Schachter","year":"1999","unstructured":"Schachter, J. et al. Toxicity of adjuvant high-dose interferon-alpha-2b in patients with cutaneous melanoma at high risk of recurrence. Oncol. Rep. 6, 1389\u20131393 (1999).","journal-title":"Oncol. Rep."},{"key":"BFnrclinonc2013153_CR56","doi-asserted-by":"publisher","first-page":"373","DOI":"10.1097\/00002371-200207000-00009","volume":"25","author":"PG Fraenkel","year":"2002","unstructured":"Fraenkel, P. G. et al. Induction of myasthenia gravis, myositis, and insulin-dependent diabetes mellitus by high-dose interleukin-2 in a patient with renal cell cancer. J. Immunother. 25, 373\u2013378 (2002).","journal-title":"J. Immunother."},{"key":"BFnrclinonc2013153_CR57","doi-asserted-by":"publisher","first-page":"412","DOI":"10.1097\/01.cji.0000171314.00924.2b","volume":"28","author":"KA Chianese-Bullock","year":"2005","unstructured":"Chianese-Bullock, K. A. et al. Autoimmune toxicities associated with the administration of antitumor vaccines and low-dose interleukin-2. J. Immunother. 28, 412\u2013419 (2005).","journal-title":"J. Immunother."},{"key":"BFnrclinonc2013153_CR58","doi-asserted-by":"publisher","first-page":"709","DOI":"10.1056\/NEJMoa053007","volume":"354","author":"H Gogas","year":"2006","unstructured":"Gogas, H. et al. Prognostic significance of autoimmunity during treatment of melanoma with interferon. N. Engl. J. Med. 354, 709\u2013718 (2006).","journal-title":"N. Engl. J. Med."},{"key":"BFnrclinonc2013153_CR59","doi-asserted-by":"publisher","first-page":"758","DOI":"10.1056\/NEJMe058307","volume":"354","author":"H Koon","year":"2006","unstructured":"Koon, H. & Atkins, M. Autoimmunity and immunotherapy for cancer. N. Engl. J. Med. 354, 758\u2013760 (2006).","journal-title":"N. Engl. J. Med."},{"key":"BFnrclinonc2013153_CR60","doi-asserted-by":"publisher","first-page":"287","DOI":"10.1097\/00002371-200107000-00004","volume":"24","author":"DJ Schwartzentruber","year":"2001","unstructured":"Schwartzentruber, D. J. Guidelines for the safe administration of high-dose interleukin-2. J. Immunother. 24, 287\u2013293 (2001).","journal-title":"J. Immunother."},{"key":"BFnrclinonc2013153_CR61","first-page":"466","volume":"51","author":"A Friebe","year":"2010","unstructured":"Friebe, A. et al. Dose-dependent development of depressive symptoms during adjuvant interferon-{alpha} treatment of patients with malignant melanoma. Psychosomatics 51, 466\u2013473 (2010).","journal-title":"Psychosomatics"},{"key":"BFnrclinonc2013153_CR62","first-page":"727","volume":"22","author":"C Pizzi","year":"2002","unstructured":"Pizzi, C. et al. Low-dose recombinant IL-2 induces psychological changes: monitoring by Minnesota Multiphasic Personality Inventory (MMPI). Anticancer Res. 22, 727\u2013732 (2002).","journal-title":"Anticancer Res."},{"key":"BFnrclinonc2013153_CR63","doi-asserted-by":"publisher","first-page":"864","DOI":"10.1634\/theoncologist.12-7-864","volume":"12","author":"J Weber","year":"2007","unstructured":"Weber, J. Review: anti-CTLA-4 antibody ipilimumab: case studies of clinical response and immune-related adverse events. Oncologist 12, 864\u2013872 (2007).","journal-title":"Oncologist"},{"key":"BFnrclinonc2013153_CR64","doi-asserted-by":"publisher","first-page":"1342","DOI":"10.1176\/appi.ajp.160.7.1342","volume":"160","author":"L Capuron","year":"2003","unstructured":"Capuron, L. et al. Association of exaggerated HPA axis response to the initial injection of interferon-alpha with development of depression during interferon-alpha therapy. Am. J. Psychiatry 160, 1342\u20131345 (2003).","journal-title":"Am. J. Psychiatry"},{"key":"BFnrclinonc2013153_CR65","doi-asserted-by":"publisher","first-page":"125","DOI":"10.1016\/S0165-1781(03)00113-6","volume":"119","author":"AR Van Gool","year":"2003","unstructured":"Van Gool, A. R. et al. Serum amino acids, biopterin and neopterin during long-term immunotherapy with interferon-alpha in high-risk melanoma patients. Psychiatry Res. 119, 125\u2013132 (2003).","journal-title":"Psychiatry Res."},{"key":"BFnrclinonc2013153_CR66","doi-asserted-by":"publisher","first-page":"555","DOI":"10.1016\/j.bbi.2004.02.002","volume":"18","author":"M Schaefer","year":"2004","unstructured":"Schaefer, M. et al. Correlation between sICAM-1 and depressive symptoms during adjuvant treatment of melanoma with interferon-alpha. Brain Behav. Immun. 18, 555\u2013562 (2004).","journal-title":"Brain Behav. Immun."},{"key":"BFnrclinonc2013153_CR67","doi-asserted-by":"publisher","first-page":"225","DOI":"10.1159\/000108382","volume":"55","author":"M Bannink","year":"2007","unstructured":"Bannink, M. et al. Interferon-alpha influences tryptophan metabolism without inducing psychiatric side effects. Neuropsychobiology 55, 225\u2013231 (2007).","journal-title":"Neuropsychobiology"},{"key":"BFnrclinonc2013153_CR68","first-page":"1871","volume":"49","author":"RL Miller","year":"1989","unstructured":"Miller, R. L. et al. Randomized trial of recombinant alpha 2b-interferon with or without indomethacin in patients with metastatic malignant melanoma. Cancer Res. 49, 1871\u20131876 (1989).","journal-title":"Cancer Res."},{"key":"BFnrclinonc2013153_CR69","doi-asserted-by":"publisher","first-page":"961","DOI":"10.1056\/NEJM200103293441303","volume":"344","author":"DL Musselman","year":"2001","unstructured":"Musselman, D. L. et al. Paroxetine for the prevention of depression induced by high-dose interferon alfa. N. Engl. J. Med. 344, 961\u2013966 (2001).","journal-title":"N. Engl. J. Med."},{"key":"BFnrclinonc2013153_CR70","doi-asserted-by":"publisher","first-page":"186","DOI":"10.1200\/JCO.2010.31.6414","volume":"29","author":"TK Poonacha","year":"2011","unstructured":"Poonacha, T. K. & Go, R. S. Level of scientific evidence underlying recommendations arising from the National Comprehensive Cancer Network clinical practice guidelines. J. Clin. Oncol. 29, 186\u2013191 (2011).","journal-title":"J. Clin. Oncol."},{"key":"BFnrclinonc2013153_CR71","doi-asserted-by":"publisher","first-page":"2443","DOI":"10.1056\/NEJMoa1200690","volume":"366","author":"SL Topalian","year":"2012","unstructured":"Topalian, S. L. et al. Safety, activity, and immune correlates of anti-PD-1 antibody in cancer. N. Engl. J. Med. 366, 2443\u20132454 (2012).","journal-title":"N. Engl. J. Med."},{"key":"BFnrclinonc2013153_CR72","doi-asserted-by":"publisher","first-page":"134","DOI":"10.1056\/NEJMoa1305133","volume":"369","author":"O Hamid","year":"2013","unstructured":"Hamid, O. et al. Safety and tumor responses with lambrolizumab (anti-PD-1) in melanoma. N. Engl. J. Med. 369, 134\u2013144 (2013).","journal-title":"N. Engl. J. Med."},{"key":"BFnrclinonc2013153_CR73","doi-asserted-by":"publisher","first-page":"2455","DOI":"10.1056\/NEJMoa1200694","volume":"366","author":"JR Brahmer","year":"2012","unstructured":"Brahmer, J. R. et al. Safety and activity of anti-PD-L1 antibody in patients with advanced cancer. N. Engl. J. Med. 366, 2455\u20132465 (2012).","journal-title":"N. Engl. J. Med."},{"key":"BFnrclinonc2013153_CR74","doi-asserted-by":"publisher","first-page":"207","DOI":"10.1016\/j.coi.2011.12.009","volume":"24","author":"SL Topalian","year":"2012","unstructured":"Topalian, S. L., Drake, C. G. & Pardoll, D. M. Targeting the PD-1\/b7-H1 (PD-L1) pathway to activate anti-tumor immunity. Curr. Opin. Immunol. 24, 207\u2013212 (2012).","journal-title":"Curr. Opin. Immunol."},{"key":"BFnrclinonc2013153_CR75","doi-asserted-by":"publisher","first-page":"122","DOI":"10.1056\/NEJMoa1302369","volume":"369","author":"JD Wolchok","year":"2013","unstructured":"Wolchok, J. D. et al. Nivolumab plus ipilimumab in advanced melanoma. N. Engl. J. Med. 369, 122\u2013133 (2013).","journal-title":"N. Engl. J. Med."},{"key":"BFnrclinonc2013153_CR76","doi-asserted-by":"publisher","first-page":"925","DOI":"10.1056\/NEJMoa1112824","volume":"366","author":"MA Postow","year":"2012","unstructured":"Postow, M. A. et al. Immunologic correlates of the abscopal effect in a patient with melanoma. N. Engl. J. Med. 366, 925\u2013931 (2012).","journal-title":"N. Engl. J. Med."},{"key":"BFnrclinonc2013153_CR77","doi-asserted-by":"publisher","first-page":"137","DOI":"10.1126\/scitranslmed.3003649","volume":"4","author":"SK Seung","year":"2012","unstructured":"Seung, S. K. et al. Phase 1 study of stereotactic body radiotherapy and interleukin-2-tumor and immunologic responses. Sci. Transl. Med. 4, 137\u2013174 (2012).","journal-title":"Sci. Transl. Med."},{"key":"BFnrclinonc2013153_CR78","doi-asserted-by":"publisher","first-page":"941","DOI":"10.2217\/fon.10.66","volume":"6","author":"HL Kaufman","year":"2010","unstructured":"Kaufman, H. L. & Bines, S. D. OPTIM trial: a phase III trial of an oncolytic herpes virus encoding GM-CSF for unresectable stage III or IV melanoma. Future Oncol. 6, 941\u2013949 (2010).","journal-title":"Future Oncol."},{"key":"BFnrclinonc2013153_CR79","doi-asserted-by":"publisher","first-page":"1509","DOI":"10.1056\/NEJMoa1215134","volume":"368","author":"SA Grupp","year":"2013","unstructured":"Grupp, S. A. et al. Chimeric antigen receptor-modified T cells for acute lymphosis leukemia. N. Engl. J. Med. 368, 1509\u20131518 (2013).","journal-title":"N. Engl. J. Med."},{"key":"BFnrclinonc2013153_CR80","doi-asserted-by":"publisher","first-page":"3027","DOI":"10.1158\/0008-5472.CAN-09-2824","volume":"70","author":"WR Burns","year":"2010","unstructured":"Burns, W. R. et al. A high molecular-weight melanoma-associated antigen-specific chimeric antigen receptor redirects lymphocytes to target human melanomas. Cancer Res. 70, 3027\u20133033 (2010).","journal-title":"Cancer Res."}],"container-title":["Nature Reviews Clinical Oncology"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/www.nature.com\/articles\/nrclinonc.2013.153.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/www.nature.com\/articles\/nrclinonc.2013.153","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/www.nature.com\/articles\/nrclinonc.2013.153.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,5,19]],"date-time":"2023-05-19T03:22:33Z","timestamp":1684466553000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/nrclinonc.2013.153"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2013,8,27]]},"references-count":80,"journal-issue":{"issue":"10","published-print":{"date-parts":[[2013,10]]}},"alternative-id":["BFnrclinonc2013153"],"URL":"https:\/\/doi.org\/10.1038\/nrclinonc.2013.153","relation":{},"ISSN":["1759-4774","1759-4782"],"issn-type":[{"value":"1759-4774","type":"print"},{"value":"1759-4782","type":"electronic"}],"subject":[],"published":{"date-parts":[[2013,8,27]]}}}